On December 25, Johnson & Johnson announced that its innovative therapeutic drug, Rikejet®, eventumab injection, has been officially approved by the National Drug Administration for the treatment of advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations.

Zhitongcaijing · 2d ago
On December 25, Johnson & Johnson announced that its innovative therapeutic drug, Rikejet®, eventumab injection, has been officially approved by the National Drug Administration for the treatment of advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations.